These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 34096005)

  • 1. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
    Grattagliano I; Di Ciaula A; Baj J; Molina-Molina E; Shanmugam H; Garruti G; Wang DQ; Portincasa P
    Methods Mol Biol; 2021; 2310():201-246. PubMed ID: 34096005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease.
    Grattagliano I; Montezinho LP; Oliveira PJ; Frühbeck G; Gómez-Ambrosi J; Montecucco F; Carbone F; Wieckowski MR; Wang DQ; Portincasa P
    Biochem Pharmacol; 2019 Feb; 160():34-45. PubMed ID: 30508523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease.
    Paradies G; Paradies V; Ruggiero FM; Petrosillo G
    World J Gastroenterol; 2014 Oct; 20(39):14205-18. PubMed ID: 25339807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
    Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
    Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper.
    Antonucci L; Porcu C; Iannucci G; Balsano C; Barbaro B
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29057834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
    Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
    Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.
    Engin A
    Adv Exp Med Biol; 2024; 1460():539-574. PubMed ID: 39287864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease.
    Lee J; Park JS; Roh YS
    Arch Pharm Res; 2019 Nov; 42(11):935-946. PubMed ID: 31571145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function.
    Yu HM; Chung HK; Park KS
    Biochem Biophys Res Commun; 2021 Jun; 558():57-63. PubMed ID: 33895552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
    Wree A; Mehal WZ; Feldstein AE
    Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies.
    Zhang CH; Zhou BG; Sheng JQ; Chen Y; Cao YQ; Chen C
    Pharmacol Res; 2020 Sep; 159():104984. PubMed ID: 32502637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.
    Di Ciaula A; Calamita G; Shanmugam H; Khalil M; Bonfrate L; Wang DQ; Baffy G; Portincasa P
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis.
    Lambrecht J; van Grunsven LA; Tacke F
    Expert Opin Pharmacother; 2020 Sep; 21(13):1637-1650. PubMed ID: 32543284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3.
    Geng Y; Wang Y; Sun R; Kang X; Zhao H; Zhu M; Sun Y; Hu Y; Wang Z; Tian X; Zhao Y; Yao J
    Toxicol Appl Pharmacol; 2021 Dec; 432():115758. PubMed ID: 34678374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL
    World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.